S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Our #1 Laser Stock for May (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
Our #1 Laser Stock for May (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Sell every Stock except ONE (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Our #1 Laser Stock for May (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
Our #1 Laser Stock for May (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Sell every Stock except ONE (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Our #1 Laser Stock for May (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
Our #1 Laser Stock for May (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Sell every Stock except ONE (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Our #1 Laser Stock for May (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
Our #1 Laser Stock for May (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Sell every Stock except ONE (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
NASDAQ:GMDA

Gamida Cell (GMDA) Stock Forecast, Price & News

$1.96
-0.02 (-1.01%)
(As of 05/26/2023 ET)
Compare
Today's Range
$1.95
$2.00
50-Day Range
$0.68
$2.22
52-Week Range
$0.56
$3.66
Volume
1.17 million shs
Average Volume
4.06 million shs
Market Capitalization
$145.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60

Gamida Cell MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
287.8% Upside
$7.60 Price Target
Short Interest
Healthy
6.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Gamida Cell in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

476th out of 1,012 stocks

Biological Products, Except Diagnostic Industry

72nd out of 169 stocks


GMDA stock logo

About Gamida Cell (NASDAQ:GMDA) Stock

Gamida Cell Ltd. is a biotechnology company specializing in developing and commercializing innovative cell therapies. With a mission to transform the lives of patients with severe hematologic and solid tumor cancers, Gamida Cell is dedicated to harnessing the power of cell therapy to provide effective and personalized treatment options.

Headquartered in Jerusalem, Israel, Gamida Cell operates globally, focusing on developing and delivering breakthrough therapies to address significant unmet medical needs. The company's flagship product, Omidubicel, is an investigational advanced cell therapy designed to enhance the outcome of bone marrow transplantation and improve the standard of care for patients with hematologic malignancies.

Gamida Cell's products and services revolve around cell therapy, with a particular emphasis on expanding and enhancing the therapeutic potential of stem cells. By leveraging its proprietary NAM-based cell expansion technology platform, the company aims to increase the number and functionality of cells for transplantation, leading to improved patient outcomes.

The company primarily targets patients with blood cancers, including leukemia, lymphoma, and myeloma, where traditional treatment options often fall short. Gamida Cell's innovative approach has garnered recognition within the medical community and has received several notable achievements, milestones, and awards. For instance, in 2022, Gamida Cell was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for Omidubicel, highlighting the therapy's potential to address a critical medical need.

It is important to note that stock performance is influenced by various factors, including news and events specific to the company. Recent news or events that may have affected Gamida Cell's share price include the publication of clinical trial data, regulatory updates, and announcements regarding partnerships or collaborations.

Looking beyond Gamida Cell's specific performance, it is essential to consider the broader industry in which the company operates. The field of cell therapy has been gaining significant attention and investment in recent years, driven by advancements in technology and the potential to revolutionize the treatment of various diseases, including cancer. Gamida Cell operates in a competitive landscape, with several other companies developing cell therapies and vying for market share.

As part of the industry analysis, it is crucial to evaluate Gamida Cell's competitive positioning and advantages relative to its peers. The company's proprietary NAM-based cell expansion technology platform sets it apart from competitors and positions it as a leader in the field. This technology allows for the expansion and enhancement of cells for transplantation, improving treatment outcomes and addressing critical unmet needs.

Gamida Cell's partnerships and collaborations with established pharmaceutical companies provide validation and access to resources that enhance its competitive advantage. These collaborations enable the company to leverage the expertise and resources of its partners to accelerate the development and commercialization of its cell therapy products.

While Gamida Cell has demonstrated growth and potential, it has risks and challenges. The biotechnology industry is highly regulated, and regulation changes or the regulatory environment can impact the development and approval of new therapies. The company must navigate complex and evolving regulatory pathways to successfully bring its products to market.

Additionally, Gamida Cell faces the challenge of staying ahead of the competition in a rapidly evolving field. Other companies also invest in cell therapies, and competitors' breakthroughs could threaten Gamida Cell's market position. Maintaining a robust research and development pipeline, protecting intellectual property, and securing strategic partnerships are vital for the company's long-term success.

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Stock News Headlines

Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Gamida Cell gets new finance chief
Gamida Cell (GMDA) Gets a Buy from H.C. Wainwright
Gamida Cell Appoints Terry Coelho as CFO
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Analyst Expectations for Gamida Cell's Future
Gamida Cell (NASDAQ:GMDA) Price Target Cut to $6.00
See More Headlines
Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Company Calendar

Last Earnings
11/15/2021
Today
5/28/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMDA
Fax
N/A
Employees
166
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.60
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+287.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-79,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.21) per share

Miscellaneous

Free Float
71,852,000
Market Cap
$145.78 million
Optionable
Not Optionable
Beta
1.62

Key Executives

  • Abigail L. Jenkins
    President, Chief Executive Officer & Director
  • Michele I. Korfin
    Chief Operating & Commercial Officer
  • Mary Theresa Coelho
    Chief Financial & Accounting Officer
  • Ronit Simantov
    Chief Medical & Scientific Officer
  • Yona Geffen
    Vice President-Research & Development













GMDA Stock - Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings
or view top-rated stocks.

What is Gamida Cell's stock price forecast for 2023?

5 equities research analysts have issued 12-month price targets for Gamida Cell's stock. Their GMDA share price forecasts range from $6.00 to $11.00. On average, they expect the company's stock price to reach $7.60 in the next year. This suggests a possible upside of 287.8% from the stock's current price.
View analysts price targets for GMDA
or view top-rated stocks among Wall Street analysts.

How have GMDA shares performed in 2023?

Gamida Cell's stock was trading at $1.29 at the start of the year. Since then, GMDA shares have increased by 51.9% and is now trading at $1.96.
View the best growth stocks for 2023 here
.

Are investors shorting Gamida Cell?

Gamida Cell saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 4,960,000 shares, a decrease of 39.5% from the April 30th total of 8,200,000 shares. Based on an average trading volume of 5,050,000 shares, the short-interest ratio is currently 1.0 days.
View Gamida Cell's Short Interest
.

When is Gamida Cell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our GMDA earnings forecast
.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd. (NASDAQ:GMDA) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.15. During the same period in the prior year, the company earned ($0.30) EPS.

What other stocks do shareholders of Gamida Cell own?
When did Gamida Cell IPO?

(GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (9.07%), BlackRock Inc. (0.20%), Leavell Investment Management Inc. (0.19%), Jane Street Group LLC (0.07%), Susquehanna International Group LLP (0.00%) and Virtu Financial LLC (0.04%). Insiders that own company stock include Abigail L Jenkins and Stephen T Wills.
View institutional ownership trends
.

How do I buy shares of Gamida Cell?

Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $1.96.

How much money does Gamida Cell make?

Gamida Cell (NASDAQ:GMDA) has a market capitalization of $145.78 million. The company earns $-79,380,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does Gamida Cell have?

The company employs 166 workers across the globe.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (713) 400-6400 or via email at irpr@gamida-cell.com.

This page (NASDAQ:GMDA) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -